NextCure (NASDAQ:NXTC) Shares Cross Above 50-Day Moving Average – Should You Sell?

Shares of NextCure, Inc. (NASDAQ:NXTC) crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $6.10 and traded as high as $6.41. NextCure shares last traded at $6.34, with a volume of 64,392 shares.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on NXTC shares. HC Wainwright reissued a “buy” rating on shares of NextCure in a research report on Thursday, August 13th. Weiss Ratings cut shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Finally, Wall Street Zen upgraded NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.00.

NextCure Stock Down 3.4%

The stock has a market capitalization of $22.79 million, a P/E ratio of -0.73 and a beta of 1.33. The company has a 50 day moving average of $6.10 and a 200-day moving average of $7.89.

NextCure (NASDAQ:NXTC) last released its earnings results on Thursday, August 6th. The company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

Insider Activity at NextCure

In related news, major shareholder Adar1 Capital Management, Llc purchased 5,626 shares of the company’s stock in a transaction dated Friday, October 23rd. The shares were acquired at an average cost of $4.83 per share, for a total transaction of $27,173.58. Following the transaction, the insider owned 728,045 shares of the company’s stock, valued at $3,516,457.35. This trade represents a 0.78% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders purchased 10,851 shares of company stock worth $53,704 over the last three months. 11.90% of the stock is currently owned by corporate insiders.

Institutional Trading of NextCure

A hedge fund recently raised its position in NextCure stock. Renaissance Technologies LLC increased its position in NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,534 shares of the company’s stock after acquiring an additional 26,900 shares during the period. Renaissance Technologies LLC owned approximately 1.68% of NextCure worth $647,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 42.65% of the company’s stock.

About NextCure

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.